Abstract
We thank Drs Dave and Narayanan for their interest in our recently published paper. 1 Gharbiya M. Giustolisi R. Allievi F. Fantozzi N. et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab—a randomized controlled trial. Am J Ophthalmol. 2010; 149: 458-464 Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar With regard to the power calculations please note the following. The population covered by the present study consists of all subjects potentially affected with myopic CNV. It is a population of modalities, and therefore, is unlimited. The sample was selected according to inclusion and exclusion criteria, mentioned in the “Methods.” From a statistical point of view, it is a simple, random, no orderly sample without replacement: it is a nonprobabilistic sample with reasoned choice, which does not allow the application of the Horvitz-Thompson estimator to estimate variance, and then errors and best sample size. We elected to enroll every eligible patient who sought treatment from February 2008 through December 2008; therefore, the sample size was left to chance. Choroidal Neovascularization in Pathologic MyopiaAmerican Journal of OphthalmologyVol. 150Issue 5PreviewWe read with interest the article titled “Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial.”1 We would like to congratulate the authors for conducting a study comparing the two treatment options for choroidal neovascularization in pathologic myopia. However, we would like to seek a few clarifications regarding the methodology and the conclusions. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
